Table 3.
Characteristics of patients with AIHA associated with PRCA
| Median age | 51.5 (0.5-76) | N = 36, unknown: 2 |
| Male/female ratio | 11:21 | N = 32, unknown: 6 |
| Treatment of AIHA | PSL, 22; Cortisone, 6; mPSL, 1; mPSL pulse, 3; MZB, 1; IVIG, 4; Plasmapheresis, 2; R-CHOP, 1; CHOP, 2; THP-COP, 1; COP, 2; VCR, 1; MACOPB, 1; | N = 33, unknown: 5 |
| Nitrogen mustard, 1; Auto, 2; Rituximab, 1; AZP, 2; CsA, 3; CPA, 2; Anabolic hormone, 1; ACTH, 2; Splenectomy, 5; Immunoadsorption, 1; Anti-lymphocyte antibodies, 1; Unknown, 5 | ||
| Complication | Congenital chromosomal abnormality/balanced reciprocal translocation, 1; SLE, 3; Rheumatoid arthritis, 2; Evan’s syndrome, 3; DM, 1; Hashimoto’s disease, 1; Retinal detachment, 1; Lymphoma, 11; MPGN, 1; Acute hepatitis A, 2; β-thalassemia, 1; Chronic lymphocytic leukemia, 1; None, 11 | N = 33, unknown: 5 |
| Interval between the onset of AIHA and the onset of PRCA (months) and the number of patients | Simultaneous, N = 18 | N = 32, unknown: 6 |
| AIHA first and PRCA later: N = 8, median interval 28 (0.75 to 96) | ||
| PRCA first and AIHA later: N = 5, median interval 6 (72 to 0.8) | ||
| Cause of PRCA | HPBV 19, 10; Thymoma, 2; WDLL, 1; Lymphoma, 1; Acute hepatitis A, 1; SLE, 1; Contrast media? 1; None, 14 | N = 37, unknown: 1 |
| Treatment of PRCA | PSL, 20; Cortisone, 6; mPSL, 2; mPSL pulse, 3; MZB, 1; IVIG, 7; Plasmapheresis, 2; R-CHOP, 1; CHOP, 2; THP-COP, 1; COP, 2; MACOPB, 1; VCR, 1; Nitrogen mustard, 1; Auto, 2; AZP, 3; CsA, 3; CPA, 1; Anabolic hormone, 1; ACTH, 3; Splenectomy, 3; Immunoadsorption, 1; Anti-lymphocyte antibodies, 1; Thymectomy, 1; None, 1; Unknown, 4 | N = 34, unknown: 4 |
| Other characteristics | Hypergammaglobulinemia, 9; Hypogammaglobulinemia, 3; Normal γ-globulin, 1; Cold agglutinins, 1 | N = 13, unknown: 25 |
mPSL methylprednisolone, MZB mizoribine, IVIG intravenous immunoglobulin, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisolone, THP-COP pirarubicin vincristine, and prednisolone, COP cyclophosphamide, vincristine, and prednisolone, VCR vincristine sulfate, MACOPB methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin, Auto autologous peripheral blood stem cell transplantation, AZP azathioprine, CsA cyclosporine A, CPA cyclophosphamide, ACTH adenocorticotropic hormone, DM diabetes mellitus, MPGN membrano proliferative glomerulonephritis.